Brent A Hanks
Overview
Explore the profile of Brent A Hanks including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
1659
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
DeVito N, Nguyen Y, Sturdivant M, Plebanek M, Villarreal K, Yarla N, et al.
Cancer Res
. 2025 Feb;
PMID: 39970333
Therapeutic resistance to immune checkpoint blockade has been commonly linked to the process of mesenchymal transformation (MT) and remains a prevalent obstacle across many cancer types. An improved mechanistic understanding...
2.
Plebanek M, Xue Y, Nguyen Y, DeVito N, Wang X, Holtzhausen A, et al.
Sci Immunol
. 2024 May;
9(95):eadi4191.
PMID: 38728412
Conventional dendritic cells (DCs) are essential mediators of antitumor immunity. As a result, cancers have developed poorly understood mechanisms to render DCs dysfunctional within the tumor microenvironment (TME). After identification...
3.
DeVito N, Nguyen Y, Sturdivant M, Plebanek M, Howell K, Yarla N, et al.
bioRxiv
. 2024 Apr;
PMID: 38617347
Significance: Gli2-induced EMT promotes immune evasion and immunotherapeutic resistance via coordinated prostaglandin and Wnt signaling.
4.
Zhou K, Hanks B, Strickler J
J Gastrointest Cancer
. 2023 Dec;
55(2):483-496.
PMID: 38133871
Background: Gastroesophageal cancer is a major cause of cancer-related mortality worldwide. Treatment of both early stage and advanced disease remains highly reliant on cytotoxic chemotherapy. About 4-24% of gastroesophageal cancers...
5.
Moore E, Blobe G, DeVito N, Hanks B, Harrison M, Hoimes C, et al.
Cancer Med
. 2023 Sep;
12(19):19394-19405.
PMID: 37712677
Background: Roughly 5% of metastatic cancers present with uncertain origin, for which molecular classification could influence subsequent management; however, prior studies of molecular diagnostic classifiers have reported mixed results with...
6.
Plebanek M, Xue Y, Nguyen Y, DeVito N, Wang X, Holtzhausen A, et al.
bioRxiv
. 2023 May;
PMID: 37162965
One Sentence Summary: The metabolic transcription factor, SREBF2, regulates the development and tolerogenic function of the mregDC population within the tumor microenvironment.
7.
Broom A, Williams Veazey L, Kenny K, Harper I, Peterie M, Page A, et al.
Clin Cancer Res
. 2023 Mar;
29(9):1670-1677.
PMID: 36920243
For three years, COVID-19 has circulated among our communities and around the world, fundamentally changing social interactions, health care systems, and service delivery. For people living with (and receiving treatment...
8.
Martin-Orozco E, Wang L, Chatterjee S, Hanks B
Front Immunol
. 2022 Dec;
13:1104167.
PMID: 36569846
No abstract available.
9.
Theivanthiran B, Yarla N, Haykal T, Nguyen Y, Cao L, Ferreira M, et al.
Sci Transl Med
. 2022 Nov;
14(672):eabq7019.
PMID: 36417489
The tumor-intrinsic NOD-, LRR- and pyrin domain-containing protein-3 (NLRP3) inflammasome-heat shock protein 70 (HSP70) signaling axis is triggered by CD8 T cell cytotoxicity and contributes to the development of adaptive...
10.
Rhodin K, Gaughan E, Raman V, Salama A, Hanks B, Shah R, et al.
Ann Surg
. 2022 Jul;
277(6):e1306-e1312.
PMID: 35797609
Objective: To determine the feasibility and impact of neoadjuvant therapy (NT) in patients who present with advanced melanoma amenable to surgical resection. Summary Background Data: Given current effective systemic therapy...